Gilead Sciences Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And…
Peering Into Gilead Sciences’s Recent Short Interest
Gilead Sciences’s (NASDAQ:GILD) short percent of float has risen 3.28% since its last report. The company recently reported…
GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows
ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…
Gilead Presents Proof-Of-Concept Data For Investigational Combination Regimen Of Lenacapavir With Broadly Neutralizing Antibodies As A Potential Twice-Yearly Approach For The Treatment Of HIV
– Study Demonstrates the Potential of Lenacapavir in Combination with Broadly Neutralizing HIV Antibodies Teropavimab and Zinlirvimab –
– Findings Support Further Evaluation of the Investigational
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 8.18% on an annualized basis…
Trodelvy Demonstrates Efficacy Treating Both Platinum-Ineligible And Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
– Oral Presentation Highlights Trodelvy Efficacy of 13.5 Months Overall Survival in Patients with Platinum-Ineligible Metastatic UC After Checkpoint Inhibitor Therapy –
– Trodelvy Demonstrated
Gilead Highlights Kite’s Tecartus CAR T-Cell Therapy Data In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial
-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months --
Gilead Sciences’ Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting
The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer. The…
‘Risk Of Overheating’: 4 Experts On Hot January Jobs Report, How The Fed Will React
The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January.
SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to $91
SVB Leerink analyst David Risinger maintains Gilead Sciences (NASDAQ:GILD) with a Market Perform and raises the price target from $81 to $91.